Last reviewed · How we verify
Capsaicin 24 Hours
At a glance
| Generic name | Capsaicin 24 Hours |
|---|---|
| Also known as | Qutenza |
| Sponsor | Hjalte Holm Andersen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke (PHASE2)
- Incidence of Dysgeusia in Breast Cancer Patients Undergoing Chemotherapy
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Response Profiles to High-concentration Capsaicin Desensitization in Patients with Peripheral Neuropathic Pain with or Without Allodynia: a Regional Multicenter Prospective Cohort
- Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients (NA)
- Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) (NA)
- The Effect of Capsaicin-induced Pain on Homeostatic Plasticity in Healthy Human Participants (NA)
- A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capsaicin 24 Hours CI brief — competitive landscape report
- Capsaicin 24 Hours updates RSS · CI watch RSS
- Hjalte Holm Andersen portfolio CI